(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of 21.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.89%.
Vir Biotechnology's revenue in 2026 is $68,556,000.On average, 11 Wall Street analysts forecast VIR's revenue for 2026 to be $35,410,880,329, with the lowest VIR revenue forecast at $26,421,782,108, and the highest VIR revenue forecast at $42,622,528,429. On average, 11 Wall Street analysts forecast VIR's revenue for 2027 to be $14,297,730,649, with the lowest VIR revenue forecast at $9,193,491,034, and the highest VIR revenue forecast at $22,661,791,466.
In 2028, VIR is forecast to generate $22,251,610,668 in revenue, with the lowest revenue forecast at $5,991,988,056 and the highest revenue forecast at $43,713,553,543.